How do you decide on the optimal neoadjuvant regimen for locally advanced GEJ cancer?  

NCCN lists CRT as category 1 but also lists chemotherapy alone as an option.  Is this decision based on discussion between surgeon and oncologist or is one approach clearly superior?



Answer from: Medical Oncologist at Academic Institution